Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain as chairman, effective immediately.Read More
In a corporate update, Vital Therapies (NASDAQ:VTL) reported that 14 subjects have been enrolled at sites in the U.S. and EU in VTL-308, the company's Phase 3 trial, designed to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis.
There are now 24 sites open for enrollment in the U.S and EU. The company expects to announce topline results in mid-2018.Read More
Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain to the board, effective immediately.
Mr. Hasnain served as president, CEO and as a director of Receptos from November 2010 to August 2015, when it was purchased by Celgene for $7.8-billion. He is currently chairman of Tocagen and Sente.Read More